Proton pump inhibitors (PPIs) are a successful class of medications accounting for $79 billion spent in the United States between 2007 and 2011.¹ While many PPI indications involve limited or short-term use, it is not uncommon for patients to use them for extended periods or for clinicians to prescribe them for indications not supported by robust evidence of efficacy. While PPIs are generally safe, even rare infectious and noninfectious adverse events² are important on a population level given their wide use.

中文翻译：

---

不再使用质子泵抑制剂：克服阻力。

质子泵抑制剂（PPI）是一类成功的药物，在2007年至2011^年期间在美国花费了790亿美元^。1尽管许多PPI适应症涉及有限或短期使用，但患者长期使用它们并不罕见期间或由临床医生开具处方，以提供没有有力的疗效证据支持的适应症。尽管PPI通常是安全的，但鉴于其广泛使用，即使是罕见的传染性和非传染性不良事件²在人群水平上也很重要。